Corcept Therapeutics Incorporated

Total Valuation

Corcept Therapeutics Incorporated carries a market capitalization of 7.80B, placing it among publicly traded companies globally. Its enterprise value stands at 3.86B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Corcept Therapeutics Incorporated currently has 107.33M shares outstanding.

Valuation Ratios

Corcept Therapeutics Incorporated trades at a trailing price-to-earnings ratio of 88.50. The price-to-sales ratio is 5.45, and the price-to-book ratio stands at 6.85.

Enterprise Valuation

On an enterprise value basis, Corcept Therapeutics Incorporated trades at an EV/EBITDA multiple of 261.26 and an EV/FCF ratio of 31.98. The EV/Sales ratio of 5.02 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 268.95 provides insight into valuation relative to core operating earnings.

Financial Position

Corcept Therapeutics Incorporated maintains a current ratio of 2.86, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Taxes

Stock Price Statistics

Corcept Therapeutics Incorporated's stock has gained approximately 4.51734% over the past 52 weeks. The 50-day moving average sits at 49.49, while the 200-day moving average is 59.46.

Income Statement

Over the trailing twelve months, Corcept Therapeutics Incorporated generated 769.10M in revenue and converted that into 47.34M in net income, yielding earnings per share of 0.41. EBITDA reached -6.19M, while operating income came in at -8.22M.

Balance Sheet

Corcept Therapeutics Incorporated holds 338.18M in cash and equivalents against 9.64M in total debt, resulting in a net debt position of -108.74M. Total book value stands at 611.77M, with working capital of 276.85M providing operational flexibility.

Cash Flow

Corcept Therapeutics Incorporated produced 120.45M in operating cash flow over the past twelve months. After subtracting -308,000.00 in capital expenditures, free cash flow totaled 120.15M - equivalent to 1.16 per share.

Margins

Corcept Therapeutics Incorporated operates with a gross margin of 98.25, reflecting its pricing power and cost economics. The operating margin of -1.07 and net profit margin of 6.16 provide insight into operational efficiency.

Dividends & Yields

Scores

Corcept Therapeutics Incorporated posts an Altman Z-Score of 16.58, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.